Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23421119 | 1.00 | CYP2C19 (0.71) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| SCHEMBL2805632 | 1.00 | CYP2C19 (0.71) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| SCHEMBL13973941 | 1.00 | CYP2C19 (0.71) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| SCHEMBL16620358 | 1.00 | CYP2C19 (0.71) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL25212312 | 0.97 | CYP2C19 (0.67) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| SCHEMBL68389 | 0.88 | CYP2D6 (0.63) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| SCHEMBL107090 | 0.88 | CYP2D6 (0.63) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| SCHEMBL18510082 | 0.88 | CYP2D6 (0.63) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL3940415 | 0.85 | TSHR (0.60) | CYP2C19ALOX15CYP1A2CYP2D6LMNA | |
| Hydrochloric Acid SCHEMBL4707097 | 0.85 | TSHR (0.60) | CYP2C19ALOX15CYP1A2CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1919911-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007021574-A1 | BICYCLIC PIPERAZINES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312240-A1 | Bicyclic Piperazines as Metabotropic Glutatmate Receptor Antagonists | GRM5, GRM1, GRIN1 | CYP2C19 3358/4885ALOX15 1653/4885CYP1A2 2506/4885 |
| US-20070037816-A1 | Bicyclic piperazines as metabotropic glutatmate receptor antagonists | GRM5, GRM1, GRIN1 | CYP2C19 3358/4885ALOX15 1653/4885CYP1A2 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.